Registered title, quoted from ClinicalTrials.gov
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 19 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 19
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
- Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
- Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
- Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
- Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
- Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
- Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
- Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
- Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
- Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
- Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
- Study siteLinYi Cancer HospitalLinyiHospital page
- Study sitePeking University People's Hospital北京大学人民医院BeijingHospital page
- Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page
- Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
- Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
- Study siteWest China Hospital四川大学华西医院ChengduHospital page
- Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
- Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07063745, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Participants must have histologically confirmed diagnosis of NSCLC and homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss.
Inclusion criterion 2
Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Inclusion criterion 3
Participants must have at least 1 measurable lesion as per RECIST v1.1.
Inclusion criterion 4
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07063745, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria
- Participants must have Metastatic (Stage IV or recurrent) non-small cell lung cancer (NSCLC) (as defined by the American Joint Committee on Cancer, Ninth Edition) with no prior systemic anti-cancer therapy for metastatic disease.
- Participants must have histologically confirmed diagnosis of NSCLC and homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss.
- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Participants must have at least 1 measurable lesion as per RECIST v1.1.
Exclusion Criteria
- Nonsquamous participants must not have documented targetable oncogenic mutation or actionable genetic alterations (AGAs) for which there is a standard of care (SoC) available as first-line (1L) therapy.
- Participants must not have symptomatic brain metastases or spinal cord compression.
- Participants must not have any prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for metastatic non-small cell lung cancer (mNSCLC).
Note: One cycle of SoC treatment prior to randomization will be allowed for participants who require immediate treatment if clinically indicated.
- Participants must not have any known or suspected impairment of gastrointestinal function that may prohibit the ability to absorb or swallow an oral medication without chewing or crushing.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Quoted from ClinicalTrials.gov, NCT07063745, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07063745, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.